Exact Sciences Corporation (EXAS) |
|
64.66 -0.75 (-1.15%)
|
03-24 12:21 |
|
Open: |
64.55 |
Pre. Close: |
65.41 |
|
High:
|
65.38 |
Low:
|
63.86 |
|
Volume:
|
376,981 |
Market Cap:
|
11,589(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 12:00:48 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 81.12 One year: 94.75 |
| Support: |
Support1: 63.29 Support2: 59.47 |
| Resistance: |
Resistance1: 69.45 Resistance2: 81.12 |
| Pivot: |
64.73 |
| Moving Average: |
MA(5): 64.83  MA(20): 64.31
MA(100): 55.55 MA(250): 49.53 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 44.3 %D(3): 47.3 |
| RSI: |
RSI(14): 51.1 |
| 52-week: |
High: 76.94 Low: 29.27 |
| Average Vol(K): |
3-Month: 2,496 (K) 10-Days: 1,762 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EXAS ] has closed above bottom band by 49.6%. Bollinger Bands are 56% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
68.03 - 68.36 |
68.36 - 68.66 |
|
Low:
|
63.84 - 64.21 |
64.21 - 64.55 |
|
Close:
|
64.82 - 65.38 |
65.38 - 65.92 |
|
Company Description |
|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. |
Headline News |
Thu, 23 Mar 2023
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research
Thu, 23 Mar 2023
Beech Hill Advisors Inc. Sells 15935 Shares of Exact Sciences Co ... - MarketBeat
Sat, 18 Mar 2023
Peregrine Capital Management LLC Grows Holdings in Exact ... - MarketBeat
Thu, 16 Mar 2023
Exact Sciences Corp (EXAS) is higher by 1.62% in a Week, Should You Accumulate? - InvestorsObserver
Tue, 14 Mar 2023
Exact Sciences (EXAS) Gains But Lags Market: What You Should ... - Nasdaq
Thu, 09 Mar 2023
Exact Sciences Corp (EXAS) is higher by 2.48% Thursday In Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
178 (M) |
| Shares Float |
176 (M) |
|
% Held by Insiders
|
0.9 (%) |
|
% Held by Institutions
|
90.4 (%) |
|
Shares Short
|
13,070 (K) |
|
Shares Short P.Month
|
11,890 (K) |
Stock Financials |
|
EPS
|
-3.49 |
|
EPS Est Next Qtl
|
-0.29 |
|
EPS Est This Year
|
-1.17 |
|
EPS Est Next Year
|
-0.71 |
|
Book Value (p.s.)
|
17.1 |
|
Profit Margin (%)
|
-30 |
|
Operating Margin (%)
|
-29.8 |
|
Return on Assets (ttm)
|
-6.1 |
|
Return on Equity (ttm)
|
-19.4 |
|
Qtrly Rev. Growth
|
16.7 |
|
Gross Profit (p.s.)
|
8.47 |
|
Sales Per Share
|
11.67 |
|
EBITDA (p.s.)
|
-2.38 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-224 (M) |
|
Levered Free Cash Flow
|
-268 (M) |
Stock Valuations |
|
PE Ratio
|
-18.6 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
3.78 |
|
Price to Sales
|
5.54 |
|
Price to Cash Flow
|
-51.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
